Thus, inhibiting CHMP2A and related pathways, it may be possible to counteract tumor resistance mechanisms and improve the therapeutic outcomes for patients suffering from various forms of cancer, including glioblastoma and head and neck squamous cell carcinoma (124). This evidence concerns the gene CHMP2A and neoplasm.